Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | PRKDC | P78527 | 3/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.32 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.30 |
| ▸ | CDK2 | P24941 | 1/20 | 0.30 |
| ▸ | TTK | P33981 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1630622 | 0.82 | GBA1 (0.41) | ROCK1ADRB3ROCK2KDM4ECDK2 | |
| SCHEMBL12724301 | 0.78 | ROCK2 (0.44) | NAMPTROCK1ROCK2KDM4EPKM | |
| SCHEMBL1631688 | 0.75 | GBA1 (0.42) | ROCK1ADRB3ROCK2CDK2 | |
| SCHEMBL1630599 | 0.75 | KDM4E (0.33) | NAMPTROCK1ROCK2NLRP3AURKB | |
| SCHEMBL1632562 | 0.72 | PDPK1 (0.40) | — | |
| SCHEMBL1631058 | 0.71 | NAMPT (0.34) | NAMPTROCK1ROCK2AURKB | |
| SCHEMBL1632639 | 0.71 | ROCK2 (0.42) | ROCK1ADRB3ROCK2CDK2LRRK2 | |
| SCHEMBL4186002 | 0.71 | GBA1 (0.46) | ROCK1ADRB3ROCK2KDM4ELRRK2 | |
| SCHEMBL1631000 | 0.69 | ROCK2 (0.40) | ROCK1ROCK2KDM4ECDK2 | |
| SCHEMBL1630888 | 0.68 | ROCK2 (0.40) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | claimed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | claimed |
| US-7932270-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2011-04-26 | — | — | US | disclosed |
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008016643-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INCORPORATED (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012126-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | NAMPT 2803/4885PRKDC 2497/4885ROCK1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.